Key Highlights
- Net loss was USD 7.6 million, or USD 0.05 per share, for the fiscal first quarter of 2027 ended September 30, 2026, against USD 5.7 million, or USD 0.11, a year earlier.
- Research and development expense rose about 87% to USD 6.7 million from USD 3.6 million, with USD 2.6 million of outside services tied to the IBIO-600 Phase 1 trial.
- Cash, cash equivalents and Debt securities totaled about USD 76.7 million, which the company says should support operations into the fourth quarter of fiscal year 2028.
- Revenue was USD 1.1 million from services to a collaborative partner versus USD 0.1 million a year earlier, while net cash used in Operating Activities rose to USD 9.4 million from USD 5.7 million.
A Wider Loss as Trial and Preclinical Spending Climb
iBio (NASDAQ:IBIO) filed its Quarterly Report on November 10, 2026 for the fiscal first quarter of 2027, which ended September 30, 2026. Revenue of USD 1.1 million came from services provided to a collaborative partner, while the company says its pipeline is not expected to produce revenue for many years, if at all. Research and Development expense was USD 6.7 million, general and administrative expense was USD 2.8 million, and total operating expenses were USD 9.4 million against USD 6.1 million. Other income of USD 0.8 million, mainly interest, narrowed the net loss to USD 7.6 million. The per-share loss fell because weighted average shares rose to about 151.6 million from about 53.0 million.
IBIO-600 in the Clinic and IBIO-610 Heading Toward First-in-Human
The company uses an AI-enabled antibody discovery platform to develop treatments for obesity and related cardiometabolic and cardiopulmonary conditions. It dosed the first participant in a Phase 1 trial of IBIO-600 in Australia in June 2026 and has completed dosing in all four single ascending dose cohorts. It expects first-in-human trials of IBIO-610, an antibody against Activin E, in the first half of calendar year 2027. In mice, the filing reports 8.9% body weight reduction with 26% lower fat mass and no measurable lean mass loss. The company says it has not completed any human trial of its therapeutic proteins, so these animal results may not carry over.
Cash Runway Into Fiscal 2028 and a Departing Medical Chief
Cash and cash equivalents were about USD 45.4 million and investments in debt securities about USD 31.2 million. The company says that supports operations into the fourth quarter of fiscal year 2028 and that earlier substantial doubt about continuing as a Going Concern has been alleviated by this liquidity. The accumulated Deficit was about USD 372.8 million. The chief medical officer left the company effective October 30, 2026, and a search for a replacement is under way. The filing lists funding sources including partnerships, out-licensing of its platform and further Equity sales, and warns that financing may not be available on favorable terms.
Where Things Stand
On the company's own estimate, yes for now. iBio (NASDAQ:IBIO) says USD 76.7 million of cash and debt securities should fund operations into the fourth quarter of fiscal year 2028, even with a quarterly cash burn of USD 9.4 million that was higher than a year ago. The loss is likely to stay wide while trial and preclinical costs rise, and the filing still lists future financing as a dependency. The next markers are IBIO-600 Phase 1 data, the IBIO-610 first-in-human start in the first half of 2027, a new chief medical officer and any partnering of the platform.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...